Skip to main content
Caplight Logo









Kestrel Therapeutics

Kestrel Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://kestreltherapeutics.com/

Last Round

Corporate Funding

Apr 28, 2026

Total Funding Raised

$48M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Kestrel Therapeutics is a biotechnology company that develops small-molecule inhibitors targeting mutant KRAS proteins for the treatment of intractable cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryKRAS inhibitoroncologysmall-molecule therapyclinical-stage biotechpan-KRAS inhibitorcancer researchclinical trialssolid tumor treatmentbiopharma partnershipdrug developmentprecision medicinetargeted therapybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kestrel Therapeutics Comparables

Compare Kestrel Therapeutics with similar companies based on industry and business-model similarity.

Kestrel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Quanta Therapeutics
85%
Jacobio Pharmaceuticals Group Co Ltd
80%
Revolution Medicines
79%

Kestrel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingApr 28, 2026
VC RoundAug 12, 2025
Convertible DebtFeb 21, 2025
Series ADec 1, 2021

Key People

Founding team and executive leadership

Frank Haluska

President And CEO

Executive Team

Kestrel Therapeutics Investors

Notable investors and investment history

Kestrel Therapeutics investors
InvestorRounds
S32Series A
Cormorant Asset ManagementSeries A
Santé VenturesVC Round, Series A
PfizerSeries A
Cormorant Asset ManagementSeries A
Pfizer VenturesVC Round, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    AbbVie led the corporate funding round.

  • Aug 12, 2025

    $5M raised from Pfizer Ventures and Santé Ventures.

Kestrel Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kestrel Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kestrel Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range23
Year Founded2020
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?